Skip to main content
Clinical Trials/NCT00599989
NCT00599989
Completed
Not Applicable

Accelerated Partial Breast Irradiation

Abramson Cancer Center at Penn Medicine1 site in 1 country28 target enrollmentJanuary 2005

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Abramson Cancer Center at Penn Medicine
Enrollment
28
Locations
1
Primary Endpoint
Acute toxicity as assessed by NCI CTC at 1 week, 4 weeks, and 3 months after completion of study therapy
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells.

PURPOSE: This clinical trial is studying the side effects of partial breast radiation therapy and how well it works in treating women undergoing breast conservation therapy for early-stage breast cancer.

Detailed Description

OBJECTIVES: * To allow women undergoing breast conservation therapy for early-stage breast cancer to have access to accelerated partial breast irradiation therapy on a controlled trial. * To capture prospective data on acute and late toxicity and disease recurrence in patients treated with this therapy. * To summarize the institutional experience of these patients treated with this experimental therapy. OUTLINE: Within 9 weeks after surgery, patients undergo accelerated partial breast irradiation (including conformal external-beam irradiation, interstitial brachytherapy, intracavitary brachytherapy, or proton beam irradiation) twice daily for 5 days (10 fractions). After completion of study therapy, patients are followed every 3 to 6 months for at least 5 years and then annually thereafter.

Registry
clinicaltrials.gov
Start Date
January 2005
End Date
May 11, 2009
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Acute toxicity as assessed by NCI CTC at 1 week, 4 weeks, and 3 months after completion of study therapy

Time Frame: 11 months

Secondary Outcomes

  • Time to locoregional recurrence(11 months)
  • Time to recurrence(11 months)
  • Late toxicity and cosmesis as assessed at or before 3 years from the start of radiotherapy and every 3 months during follow-up(11 months)
  • Site of disease recurrence (i.e., local, regional, or distant)(11 months)

Study Sites (1)

Loading locations...

Similar Trials